Pharmaceutical Executive-01-01-2021

With a complicated and challenging global picture greeting the new year, driven by the continuing pandemic and historic political and regulatory changes in the US and Europe, we outline eight diverse trends critical to biopharma’s future health and growth.

How biopharma manufacturers can address extreme pricing of novel rare disease medicines and build legitimacy into commercialization to avoid an industrywide crisis.

Data suggests physicians just as hesitant as patients, but recent successes could turn the tide.

Industry’s tardy shift to cloud-based solutions looks set to gather pace in 2021.

Biopharma sustainability resolutions for a better 2021.

Deeply shaped by the experiences of his parents and an early charge to help drive social change, Global Blood Therapeutics’ Ted Love comes at sickle cell disease from a place of caring and urges pharma to follow suit to bring justice to all.

Click the title above for a link to open the Pharmaceutical Executive January 2021 issue in an interactive PDF format.

Biden administration faces key decisions on drug testing and access amid vaccine distribution challenges.

Embracing the new, holistic views of pharma in 2021.

The need to prioritize digital skill-building companywide.

Looking back at 1981.

EU tasked with translating bold declarations into reality.

Tone still set on the market catalysts to look for in 2021.